表紙
市場調查報告書

CD40配體 (T細胞抗原GP40、TNF相關活性化蛋白質、腫瘤壞死因子配體超級家族5號、CD154、CD40LG):開發中產品分析

CD40 Ligand - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 363562
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
CD40配體 (T細胞抗原GP40、TNF相關活性化蛋白質、腫瘤壞死因子配體超級家族5號、CD154、CD40LG):開發中產品分析 CD40 Ligand - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 74 Pages
簡介

本報告提供全球各國的CD40配合基 (別名T細胞抗原GP40或TNF相關活性化蛋白質,腫瘤壞死因子配體超級家族5號,CD154,為您概述為以下內容CD40LG)的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • CD40配體 (T細胞抗原GP40、TNF相關活性化蛋白質、腫瘤壞死因子配體超級家族5號、CD154、CD40LG)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Biogen, Inc.
    • Bristol-Myers Squibb Company
    • eTheRNA Immunotherapies NV
    • ImmuNext, Inc.
    • Juno Therapeutics Inc.
    • MedImmune, LLC
    • Targovax AS
    • XL-protein GmbH
  • 藥物簡介
    • 自體免疫疾病、GVHD用CD40L較量用抗體
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • 免疫疾病用CD40配體標的抗體
    • BIIB-063
    • BMS-986004
    • CD40L活性化用及B細胞惡性手法標的用細胞免疫療法
    • FFP-102
    • B型肝炎疫苗
    • ISF-35
    • LOAd-700
    • MEDI-4920
    • MegaCD40L
    • 腫瘤、感染疾病用CD40L、CD70、TLR-4活性化用寡核苷酸
    • ONCOS-402
    • TDI-28
    • TDI-846
    • UltraCD40L
    • 腫瘤用CD40L、GM-CSF標的疫苗
    • XL-050
  • 開發暫停的產品
  • 值得注意的最新趨勢、新聞稿 (共10件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2042TDB

Summary

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells.

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 5 and 7 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System and Genetic Disorders which include indications Autoimmune Disorders, Graft Versus Host Disease (GVHD), Amyotrophic Lateral Sclerosis, Breast Cancer, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Auto Inflammatory Disease, Bladder Cancer, Colon Cancer, Hepatocellular Carcinoma, Inflammation, Kidney Transplant Rejection, Lung Adenocarcinoma, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Pancreatic Islet Transplant Rejection, Sicca Syndrome (Sjogren), Solid Tumor and Transplant Rejection.

The latest report CD40 Ligand - Pipeline Review, H2 2019, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
  • The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects
  • The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development
  • Anelixis Therapeutics LLC
  • Bristol-Myers Squibb Co
  • eTheRNA Immunotherapies NV
  • Memgen LLC
  • NapaJen Pharma Inc
  • Sanofi
  • Shattuck Labs Inc
  • TILT Biotherapeutics Ltd
  • Tonix Pharmaceuticals Holding Corp
  • UCB SA
  • Viela Bio Inc
  • XL-protein GmbH
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles
  • AT-1501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dapirolizumab pegol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ECI-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Proteins for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate CD40LG for Genetic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target CD40 Ligand for Malignant Melanoma and Bladder Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ISF-35 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • letolizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NJA-730 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-441344 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-115154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-172154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TDI-28 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TILT-234 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TNX-1500 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VIB-4920 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XL-050 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Products
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Discontinued Products
  • CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 11, 2019: Viela Bio announces initiation of phase 2b trial of VIB4920 in Sjogren's Syndrome
  • Nov 08, 2019: UCB Presents new data on investigational molecule Dapirolizumab Pegol at the 2019 American College of Rheumatology and the Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
  • Aug 21, 2019: Tonix Pharmaceuticals and Massachusetts General Hospital enter into research collaboration to develop Tonixs third generation anti-CD154 monoclonal antibody, TNX-1500, for the treatment and prevention of organ transplant rejection
  • Jun 01, 2019: Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL
  • Mar 04, 2019: eTheRNA immunotherapies completes patient enrolment for Phase Ib-study in adjuvant melanoma
  • Nov 28, 2018: Augie's Quest reports first subject successfully enrolled in AT-1501 phase 1 study, a first-of-its-kind, promising treatment for ALS
  • Nov 15, 2018: NapaJen Pharma announces first patient dosed in phase 1 first-in-human clinical trial of novel RNA interference (RNAi) therapeutic
  • Oct 23, 2018: UCB and Biogen announce topline results from a phase 2b study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
  • Oct 19, 2018: Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920 at the 2018 ACR/ARHP Annual Meeting
  • Oct 08, 2018: eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies
  • May 24, 2018: eTheRNA Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
  • Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma
  • Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies
  • Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)
  • Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Anelixis Therapeutics LLC, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by eTheRNA Immunotherapies NV, H2 2019
  • Pipeline by Memgen LLC, H2 2019
  • Pipeline by NapaJen Pharma Inc, H2 2019
  • Pipeline by Sanofi, H2 2019
  • Pipeline by Shattuck Labs Inc, H2 2019
  • Pipeline by TILT Biotherapeutics Ltd, H2 2019
  • Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2019
  • Pipeline by UCB SA, H2 2019
  • Pipeline by Viela Bio Inc, H2 2019
  • Pipeline by XL-protein GmbH, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top